regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
On July 16, 2021, the Grand Commander of the Supreme Council of Cuba at the time, José Ramón Viñas Alonso, wrote another letter to President Miguel Díaz-Canel. This one was much more direct than the Grand Master's letter, and outright rejected the authority of the President of Cuba. In the letter, he admonished the President's choices and actions during the event, and condemned what he called government repression of the protest. He wrote that in the Supreme Council's considered opinion, President Díaz-Canel had intentionally and purposefully sent armed government police to use violence against the Cuban people, to arrest peaceful demonstrators, and to curtail the voice of anyone who "...thinks contrary to the system that you represent..." Even more critically, Viñas Alonso accused the President of using the United States embargo against Cuba as an excuse for any lack of ability that the Cuban government possessed in the day-to-day governing of the country, and that in doing so, the President avoided truly addressing the ineffectiveness of the government.Later in the afternoon of July 16, Grand Commander Viñas Alonso was summoned to Castro Police Station at the corner of Calle Unidad (English: Unidad Street) and Calle C (English: C Street) in Plaza de la Revolución. At the police station, Viñas Alonso was interrogated by three federal agents of the State Security Unit. In August 2021, Grand Master Ernesto Zamora Fernández was invited to attend a private meeting with Díaz-Canel, but Grand Commander Viñas Alonso was not invited.
=== Afghanistan === In Afghanistan, the residency (Dari, تخصص) consists of a three to seven years of practical and research activities in the field selected by the candidate. The graduate medical students do not need to complete the residency because they study medicine in six years (three years for clinical subjects, three years clinical subjects in hospital) and one-year internship and they graduate as general practitioner. Most students do not complete residency because it is too competitive.
== Overdose == Symptoms of overdose are due to excessive pharmacodynamic actions on β1-receptors, and with loss of cardioselectivity at high concentrations, β2-receptors. These include bradycardia (slow heartbeat), severe hypotension with shock, acute heart failure, hypoglycemia and bronchospastic reactions. Treatment is largely symptomatic. Hospitalization and intensive monitoring is indicated. Activated charcoal is useful to absorb the drug. Atropine will counteract bradycardia, glucagon helps with hypoglycemia, dobutamine can be given against hypotension and the inhalation of a β2-mimetic such as hexoprenalin or salbutamol will terminate bronchospasms. Blood or plasma atenolol concentrations may be measured to confirm a diagnosis of poisoning in hospitalized patients or to assist in a medicolegal death investigation. Plasma levels are usually less than 3 mg/L during therapeutic administration, but can range from 3–30 mg/L in overdose victims.
=== Lymphatic malformation (LM) === Lymphatic malformation, lymphangioma or cystic hygroma, is an abnormal growth of lymphatic vessels that usually affects children around the head and neck area and more rarely involving the tongue causing macroglossia. LM is caused by a PIK3CA mutation during lymphangiogenesis early in gestational cell formation causing the malformation of lymphatic tissue. Treatment often consists of removal of the affected tissue via excision, laser ablation or sclerotherapy, but the rate of recurrence can be high and surgery can have complications. Sirolimus has shown evidence of being an effective treatment in alleviating symptoms and reducing the size of the malformation by way of altering the mTOR pathway in lymphangiogenesis. Although an off label use of the drug, Sirolimus has been shown to be an effective treatment for both microcystic and macrocystic LM. More research is however needed to develop and create targeted, effective treatment therapies for LM.
Sources: en.wikipedia.org
As of 2004, it was thought that "uniquely" among 17α-alkylated AASs, oxandrolone showed little to no hepatotoxicity, even at high doses. However, elevated liver enzymes have been observed in some people, particularly with high doses and/or prolonged treatment, although sometimes returning to normal ranges following discontinuation. However, there have been documented severe cases of peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver tumors, sometimes fatal; and blood lipid changes associated with increased risk of atherosclerosis. This led the FDA to remove approval in June 2023. Additional warnings include the risks associated with cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in older patients. Women who are administered oxandrolone may experience virilization, irreversible development of masculine features such as voice deepening, hirsutism, menstruation abnormalities, male-pattern hair loss, and clitoral enlargement. Because of these side effects, doses given to women and children are minimized and people are usually monitored for virilization and growth abnormalities. Like other androgens, oxandrolone can cause or worsen acne and priapism (unwanted or prolonged erections). Oxandrolone can also reduce males' fertility, another side effect common among androgens.
==== Silver ion tablets ==== An alternative to iodine-based preparations in some usage scenarios are silver ion/chlorine dioxide-based tablets or droplets. These solutions may disinfect water more effectively than iodine-based techniques while leaving hardly any noticeable taste in the water in some usage scenarios. Silver ion/chlorine dioxide-based disinfecting agents will kill Cryptosporidium and Giardia, if utilized correctly. The primary disadvantage of silver ion/chlorine dioxide-based techniques is the long purification times (generally 30 minutes to 4 hours, depending on the formulation used). Another concern is the possible deposition and accumulation of silver compounds in various body tissues leading to a rare condition called argyria that results in a permanent, disfiguring, bluish-gray pigmentation of the skin, eyes, and mucous membranes.
His publications also highlight the importance of patient happiness, as well as the well-being of the treating physician. Strengthening family support, advancing social acceptance, and addressing patient emotions are other elements he considers essential to delivering person-centred care.69 He has also highlighted the value of indigenous methods for lifestyle modification and personal hygiene in improving person-centred care.123,166 Kalra has proposed several frameworks to help clinicians integrate the above principles into routine practice.129,161,162 These frameworks have been widely cited. In collaboration with researchers in Morocco, he published the SURE framework outlining the “glycaemic personality” of patients, enabling more tailored therapeutic choices. In another publication, he described the Motivation–Opportunity–Capability (MOC) model for obesity care, underscoring the importance of understanding patient behaviour and aligning therapeutic approaches with their opportunities and capabilities. Kalra’s contribution to original research includes participation in multicentric international collaborative studies that have advanced understanding of person-centred management. In the three-year, pan-India longitudinal study on diabetes outcomes (the LANDMARC trial), data are being collected on trends in diabetic complications, physician treatment strategies, and correlations between treatment, control, and complications in the Indian setting.
Sources: en.wikipedia.org
== Treatment == The first step in treatment following a honey bee sting is removal of the stinger itself. The stinger should be removed as quickly as possible without regard to method: a study has shown the amount of venom delivered does not differ whether the sting is pinched or scraped off and even a delay of a few seconds leads to more venom being injected. Once the stinger is removed, pain and swelling should be reduced with a cold compress. A topical anesthetic containing benzocaine will relieve pain quickly and menthol is an effective anti-itch treatment. Itching can also be relieved by antihistamine or by a topical steroid cream. Many traditional remedies have been suggested for bee stings. No interventions have been proven to be effective in scientific studies and a randomized trial of aspirin paste and topical ice packs showed that aspirin was not effective in reducing the duration of swelling or pain in bee and wasp stings, and significantly increased the duration of redness. The study concluded that ice alone is a better treatment for bee and wasp stings than aspirin. For about 2 percent of people, a hypersensitivity can develop after being stung, creating a more severe reaction. This sensitisation may happen after a single sting, or after a series of stings. An allergic person may suffer anaphylactic shock from certain proteins in the venom, which can be life-threatening and requires emergency treatment.
Ultrasound-assisted extractive electrospray ionization mass spectrometry (EESI-MS) has been developed at ETH Zurich (Switzerland) by Zhu, Chingin et al., (2008) for a rapid detection of melamine in untreated food samples. Ultrasounds are used to nebulize the melamine-containing liquids into a fine spray. The spray is then ionised by extractive electrospray ionisation (EESI) and analysed using tandem mass spectrometry (MS/MS). An analysis requires 30 seconds per sample. The limit of detection of melamine is a few nanograms of melamine per gram of milk. Huang et al. (2008) have also developed at Purdue University (US) a simpler instrumentation and a faster method by using a low-temperature plasma probe to ionize the samples. The major obstacles being solved, the ESI-MS technique allows now high-throughput analysis of melamine traces in complex mixtures. The Melaminometer was a hypothetical design for a synthetic biology circuit, to be used for detecting melamine and related chemical analogues such as cyanuric acid. The conceptual project is hosted at OpenWetWare as open source biology in collaboration with DIYbio and has been discussed in various newspapers in the context of homebrew biotechnology. As of October 2009, the design has not been verified. Because melamine resin is often used in food packaging and tableware, melamine at ppm level (1 part per million) in food and beverage has been reported due to migration from melamine-containing resins.
is constant throughout the change. Additionally, the Rahemi–Li model links the temperature dependence of Young’s modulus in metals to changes in the electron work function, providing a theoretical basis using a generalized Lennard-Jones potential.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.